Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Antimicrobial Agents and Chemotherapy
|
March 18, 2020
Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis
Vidmantas Petraitis, Ruta Petraitiene, Aspasia Katragkou, et al.
Antimicrobial Agents and Chemotherapy
|
February 23, 2017
The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation
Emily Larkin, Christopher Hager, Jyotsna Chandra, et al.
Antimicrobial Agents and Chemotherapy
|
February 1, 2017
Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis
Stephen A Wring, Ryan Randolph, SeongHee Park, et al.
Antibiotics (Basel, Switzerland)
|
August 29, 2020
Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of <i>Candida auris</i> Infections
Mahmoud Ghannoum, Maiken Cavling Arendrup, Vishnu P Chaturvedi, et al.
The New England Journal of Medicine
|
January 26, 2007
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
Oliver A Cornely, Johan Maertens, Drew J Winston, et al.
Nature Neuroscience
|
August 31, 2023
Prominent in vivo influence of single interneurons in the developing barrel cortex
Yannick Bollmann, Laura Modol, Thomas Tressard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 15, 2021
FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs
Elizabeth O'Shaughnessy, Yuliya Yasinskaya, Cheryl Dixon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 6, 2023
Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need
Yuliya Yasinskaya, Shukal Bala, Ursula Waack, et al.
Frontiers in Cellular and Infection Microbiology
|
June 2, 2022
<i>In Vitro</i> Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of <i>Candida</i>: A European Study
Guillermo Quindós, Katherine Miranda-Cadena, Rosario San-Millán, et al.
Tropical Medicine and Infectious Disease
|
April 27, 2026
Yellow Fever in Pregnancy: A Comprehensive Review of the Clinical Implications and Vaccination in the Context of the 2024-2026 Americas Outbreak
Alfonso J Rodríguez-Morales, Katherine Acevedo-Jimenez, María Eugenia Guevara, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Antimicrobial Agents and Chemotherapy
|
March 18, 2020
Combination Therapy with Ibrexafungerp (Formerly SCY-078), a First-in-Class Triterpenoid Inhibitor of (1→3)-β-d-Glucan Synthesis, and Isavuconazole for Treatment of Experimental Invasive Pulmonary Aspergillosis
Vidmantas Petraitis, Ruta Petraitiene, Aspasia Katragkou, et al.
Antimicrobial Agents and Chemotherapy
|
February 23, 2017
The Emerging Pathogen Candida auris: Growth Phenotype, Virulence Factors, Activity of Antifungals, and Effect of SCY-078, a Novel Glucan Synthesis Inhibitor, on Growth Morphology and Biofilm Formation
Emily Larkin, Christopher Hager, Jyotsna Chandra, et al.
Antimicrobial Agents and Chemotherapy
|
February 1, 2017
Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis
Stephen A Wring, Ryan Randolph, SeongHee Park, et al.
Antibiotics (Basel, Switzerland)
|
August 29, 2020
Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of <i>Candida auris</i> Infections
Mahmoud Ghannoum, Maiken Cavling Arendrup, Vishnu P Chaturvedi, et al.
The New England Journal of Medicine
|
January 26, 2007
Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia
Oliver A Cornely, Johan Maertens, Drew J Winston, et al.
Nature Neuroscience
|
August 31, 2023
Prominent in vivo influence of single interneurons in the developing barrel cortex
Yannick Bollmann, Laura Modol, Thomas Tressard, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
October 15, 2021
FDA Public Workshop Summary-Coccidioidomycosis (Valley Fever): Considerations for Development of Antifungal Drugs
Elizabeth O'Shaughnessy, Yuliya Yasinskaya, Cheryl Dixon, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
April 6, 2023
Food and Drug Administration Public Workshop Summary-Development Considerations of Antifungal Drugs to Address Unmet Medical Need
Yuliya Yasinskaya, Shukal Bala, Ursula Waack, et al.
Frontiers in Cellular and Infection Microbiology
|
June 2, 2022
<i>In Vitro</i> Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of <i>Candida</i>: A European Study
Guillermo Quindós, Katherine Miranda-Cadena, Rosario San-Millán, et al.
Tropical Medicine and Infectious Disease
|
April 27, 2026
Yellow Fever in Pregnancy: A Comprehensive Review of the Clinical Implications and Vaccination in the Context of the 2024-2026 Americas Outbreak
Alfonso J Rodríguez-Morales, Katherine Acevedo-Jimenez, María Eugenia Guevara, et al.
Page
of 5